A study of more than two million people with diabetes builds on evidence of broad-ranging benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the clinical setting, providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback